Ghrelin receptor agonist (TZP-101) accelerates gastric emptying in adults with diabetes and symptomatic gastroparesis

What Was Tested

This randomized controlled trial paper looks at Ghrelin.

To assess safety and effects of TZP-101 in diabetes patients with symptomatic gastroparesis.

Why It Was Studied

TZP-101 is a synthetic, selective ghrelin agonist in development for gastroparesis.

Who Took Part

The study group was 101 patients.

By PubMed's age tags, the people studied were teenagers, young adults, adults, middle-aged adults and older adults, both men and women.

Secondary measures included assessment of gastroparesis symptoms and endocrine responses.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and crossover study.

Because people in this Ghrelin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the patients and researchers unaware of who received Ghrelin.

Some patients received a placebo instead of Ghrelin, giving a reference point.

Each person switched between Ghrelin and the comparison at some point, usually with a gap in between.

Blood glucose levels were stabilized using a hyperinsulinemic-euglycemic clamp.

Primary endpoints were gastric half emptying and latency times.

What Was Measured

Topics PubMed links to this paper include Blood Glucose, Diabetes Complications, Gastric Emptying, Gastroparesis, Ghrelin, Glucose Clamp Technique and Macrocyclic Compounds.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Ghrelin in 101 patients.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2009 (Alimentary pharmacology & therapeutics), a journal based in England.

More context: the Ghrelin compound page, all human trials.